Compare DNUT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | DCTH |
|---|---|---|
| Founded | 1937 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.0M | 578.4M |
| IPO Year | 2021 | 2015 |
| Metric | DNUT | DCTH |
|---|---|---|
| Price | $2.82 | $14.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $4.08 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 1.9M | 251.9K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $1,522,616,000.00 | N/A |
| Revenue This Year | N/A | $24.61 |
| Revenue Next Year | $5.20 | $24.27 |
| P/E Ratio | ★ N/A | $368.38 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $8.12 |
| 52 Week High | $4.75 | $17.42 |
| Indicator | DNUT | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 39.08 |
| Support Level | N/A | $14.26 |
| Resistance Level | $3.72 | $16.51 |
| Average True Range (ATR) | 0.12 | 0.51 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 2.70 | 17.28 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.